table of content
1 Introduction to Research & Analysis Reports
1.1 Circulating Tumor DNA Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Circulating Tumor DNA Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Circulating Tumor DNA Diagnostics Overall Market Size
2.1 Global Circulating Tumor DNA Diagnostics Market Size: 2022 VS 2030
2.2 Global Circulating Tumor DNA Diagnostics Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Circulating Tumor DNA Diagnostics Players in Global Market
3.2 Top Global Circulating Tumor DNA Diagnostics Companies Ranked by Revenue
3.3 Global Circulating Tumor DNA Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Circulating Tumor DNA Diagnostics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Circulating Tumor DNA Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Circulating Tumor DNA Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Circulating Tumor DNA Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Circulating Tumor DNA Diagnostics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Circulating Tumor DNA Diagnostics Market Size Markets, 2022 & 2030
4.1.2 Test Kits
4.1.3 Reagents
4.2 By Type - Global Circulating Tumor DNA Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Circulating Tumor DNA Diagnostics Revenue, 2018-2023
4.2.2 By Type - Global Circulating Tumor DNA Diagnostics Revenue, 2023-2030
4.2.3 By Type - Global Circulating Tumor DNA Diagnostics Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Circulating Tumor DNA Diagnostics Market Size, 2022 & 2030
5.1.2 Hospitals
5.1.3 Diagnostics Laboratories
5.1.4 Research Laboratories
5.1.5 Academic Research Institutes
5.2 By Application - Global Circulating Tumor DNA Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Circulating Tumor DNA Diagnostics Revenue, 2018-2023
5.2.2 By Application - Global Circulating Tumor DNA Diagnostics Revenue, 2023-2030
5.2.3 By Application - Global Circulating Tumor DNA Diagnostics Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Circulating Tumor DNA Diagnostics Market Size, 2022 & 2030
6.2 By Region - Global Circulating Tumor DNA Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Circulating Tumor DNA Diagnostics Revenue, 2018-2023
6.2.2 By Region - Global Circulating Tumor DNA Diagnostics Revenue, 2023-2030
6.2.3 By Region - Global Circulating Tumor DNA Diagnostics Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Circulating Tumor DNA Diagnostics Revenue, 2018-2030
6.3.2 US Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.3.3 Canada Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.3.4 Mexico Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Circulating Tumor DNA Diagnostics Revenue, 2018-2030
6.4.2 Germany Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.4.3 France Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.4.4 U.K. Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.4.5 Italy Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.4.6 Russia Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.4.7 Nordic Countries Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.4.8 Benelux Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Circulating Tumor DNA Diagnostics Revenue, 2018-2030
6.5.2 China Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.5.3 Japan Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.5.4 South Korea Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.5.5 Southeast Asia Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.5.6 India Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Circulating Tumor DNA Diagnostics Revenue, 2018-2030
6.6.2 Brazil Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.6.3 Argentina Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Circulating Tumor DNA Diagnostics Revenue, 2018-2030
6.7.2 Turkey Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.7.3 Israel Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.7.4 Saudi Arabia Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.7.5 UAE Circulating Tumor DNA Diagnostics Market Size, 2018-2030
7 Players Profiles
7.1 Grail, Inc.
7.1.1 Grail, Inc. Corporate Summary
7.1.2 Grail, Inc. Business Overview
7.1.3 Grail, Inc. Circulating Tumor DNA Diagnostics Major Product Offerings
7.1.4 Grail, Inc. Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.1.5 Grail, Inc. Key News
7.2 Guardant Health, Inc.
7.2.1 Guardant Health, Inc. Corporate Summary
7.2.2 Guardant Health, Inc. Business Overview
7.2.3 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Major Product Offerings
7.2.4 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.2.5 Guardant Health, Inc. Key News
7.3 Biodesix, Inc.
7.3.1 Biodesix, Inc. Corporate Summary
7.3.2 Biodesix, Inc. Business Overview
7.3.3 Biodesix, Inc. Circulating Tumor DNA Diagnostics Major Product Offerings
7.3.4 Biodesix, Inc. Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.3.5 Biodesix, Inc. Key News
7.4 Exosome Diagnostics
7.4.1 Exosome Diagnostics Corporate Summary
7.4.2 Exosome Diagnostics Business Overview
7.4.3 Exosome Diagnostics Circulating Tumor DNA Diagnostics Major Product Offerings
7.4.4 Exosome Diagnostics Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.4.5 Exosome Diagnostics Key News
7.5 Freenome Inc.
7.5.1 Freenome Inc. Corporate Summary
7.5.2 Freenome Inc. Business Overview
7.5.3 Freenome Inc. Circulating Tumor DNA Diagnostics Major Product Offerings
7.5.4 Freenome Inc. Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.5.5 Freenome Inc. Key News
7.6 LungLife AI, Inc.
7.6.1 LungLife AI, Inc. Corporate Summary
7.6.2 LungLife AI, Inc. Business Overview
7.6.3 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Major Product Offerings
7.6.4 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.6.5 LungLife AI, Inc. Key News
7.7 Inivata Ltd.
7.7.1 Inivata Ltd. Corporate Summary
7.7.2 Inivata Ltd. Business Overview
7.7.3 Inivata Ltd. Circulating Tumor DNA Diagnostics Major Product Offerings
7.7.4 Inivata Ltd. Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.7.5 Inivata Ltd. Key News
7.8 Personal Genome Diagnostics, Inc.
7.8.1 Personal Genome Diagnostics, Inc. Corporate Summary
7.8.2 Personal Genome Diagnostics, Inc. Business Overview
7.8.3 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Major Product Offerings
7.8.4 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.8.5 Personal Genome Diagnostics, Inc. Key News
7.9 CellMax Life
7.9.1 CellMax Life Corporate Summary
7.9.2 CellMax Life Business Overview
7.9.3 CellMax Life Circulating Tumor DNA Diagnostics Major Product Offerings
7.9.4 CellMax Life Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.9.5 CellMax Life Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
